- Home
- DRRX vs FEMY Comparison
DRRX vs FEMY Comparison
Compare DRRX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- FEMY
- Stock Information
- Founded
- DRRX 1998
- FEMY 2004
- Country
- DRRX United States
- FEMY United States
- Employees
- DRRX N/A
- FEMY N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- DRRX Health Care
- FEMY Health Care
- Exchange
- DRRX Nasdaq
- FEMY Nasdaq
- Market Cap
- DRRX N/A
- FEMY 31.9M
- IPO Year
- DRRX 2000
- FEMY 2021
- Fundamental
- Price
- DRRX $0.61
- FEMY $0.91
- Analyst Decision
- DRRX Hold
- FEMY Strong Buy
- Analyst Count
- DRRX 1
- FEMY 3
- Target Price
- DRRX N/A
- FEMY $8.67
- AVG Volume (30 Days)
- DRRX 47.0K
- FEMY 280.4K
- Earning Date
- DRRX 08-12-2025
- FEMY 08-07-2025
- Dividend Yield
- DRRX N/A
- FEMY N/A
- EPS Growth
- DRRX N/A
- FEMY N/A
- EPS
- DRRX N/A
- FEMY N/A
- Revenue
- DRRX $1,856,000.00
- FEMY $1,699,232.00
- Revenue This Year
- DRRX N/A
- FEMY $231.84
- Revenue Next Year
- DRRX $673.00
- FEMY $245.28
- P/E Ratio
- DRRX N/A
- FEMY N/A
- Revenue Growth
- DRRX 79.84
- FEMY 61.97
- 52 Week Low
- DRRX $0.48
- FEMY $0.69
- 52 Week High
- DRRX $1.74
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- DRRX 46.88
- FEMY 50.88
- Support Level
- DRRX $0.57
- FEMY $0.90
- Resistance Level
- DRRX $0.69
- FEMY $0.99
- Average True Range (ATR)
- DRRX 0.06
- FEMY 0.07
- MACD
- DRRX -0.00
- FEMY 0.01
- Stochastic Oscillator
- DRRX 48.12
- FEMY 39.48
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.